section name header

Interacting Drugs

OBJECT DRUGS

PRECIPITANT DRUGS

Enzyme Inhibitors:


Comment:

Eliglustat is metabolized by CYP3A4, and CYP3A4 inhibitors may increase the risk of eliglustat toxicity. Since eliglustat is also a CYP2D6 substrate, the effect of CYP3A4 inhibitors is likely to be greater in patients who also receiving CYP2D6 inhibitors, or who have genotypes leading to reduced CYP2D6 activity. Testing for CYP2D6 genotype is required prior to eliglustat treatment, and the management recommendations are different depending on whether the patient is an extensive metabolizer (EM), intermediate metabolizer (IM) or poor metabolizer (PM). See below. Also, the eliglustat label (2014) states that concurrent use of CYP2D6 inhibitors and CYP3A4 inhibitors is contraindicated in patients taking eliglustat.


Class 2: Use Only if Benefit Felt to Outweigh Risk